April 2025 Targeted Pulse

EP. 1: The Targeted Pulse: New Approvals Are Advancing the Field, and the MARIPOSA Trial Continues to Deliver

ByMorgan Bayer

April 6th 2025

The FDA approved agents in MIBC and neuroendocrine tumors and amivantamab/lazertinib continues to shine in NSCLC.

EP. 2: The Targeted Pulse: SC Pembrolizumab Combo Matches SOC in NSCLC and CAR T-cells Transform the Solid Tumor Space

ByMorgan Bayer

April 13th 2025

Chemotherapy/Pembrolizumab SC shows noninferior to SOC in NSCLC, expert insights on advances with CAR T-cells, and a full approval for gastric cancer.

EP. 3: The Targeted Pulse: FDA Approvals in HCC and CRC, Promise for SCLC, and More

BySabrina Serani

April 20th 2025

The week marked several FDA approvals for drugs and devices, plus data continues to show tarlatamab’s benefit in small cell lung cancer.

EP. 4: The Targeted Pulse: AI Cancer Diagnosis, Breast Cancer Treatment Updates, and More

BySabrina Serani

April 27th 2025

Antibody-drug conjugates continue to show benefits in breast cancer, plus the FDA has fast-tracked an innovative AI tool to help identify pancreatic tumors.